Traitements locorégionaux des sites métastatiques chez des patients atteints d’un mélanome pauci-métastatique (hors métastase cérébrale) : recommandations nationales françaises
B. Sassolas(Centre Hospitalier Régional Universitaire de Brest), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Inna Dygai‐Cochet(Centre Georges François Leclerc), X. Mirabel(American Society of Clinical Oncology), P. Modiano(Institut de Cancérologie de l'Ouest), Marie-Ève Rougé Bugat, G. Truc(Centre Georges François Leclerc), Laurence Lamant(Centre National de la Recherche Scientifique), V. Mazeau-Woynar(Institut National du Cancer), V. Lubrano(Université Toulouse III - Paul Sabatier), Juliette Thariat(Centre National de la Recherche Scientifique), P. Combemale(Centre Léon Bérard), Anne Mourrégot(Institut de Recherche en Cancérologie de Montpellier), L. Verdoni, Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), François Planchamp, Olivier Tiffet(Centre Hospitalier Universitaire de Saint-Étienne), Sophie Siegrist, Stéphane Derrey(Inserm), C. Bédane(Central Michigan University)
Cited by 0
Related Papers
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
|Journal of Clinical Oncology|2012|434
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
|The Lancet Oncology|2015|394
French guidelines on stereoelectroencephalography (SEEG)
|Neurophysiologie Clinique|2017|348